• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump

November 18, 2021 By Sean Whooley

Bexson Biomedical Ketamine Pump
Bexson is developing a wearable infusion pump with Stevanato Group. (Image from Bexson)

Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy.

Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group.

According to a news release, having reached the milestone of pre-IND guidance, Bexson plans to expand its ketamine development program to address mental health conditions including treatment-resistant depression and suicidality.

“We are pleased with the clear guidance we received from FDA regarding our preclinical and clinical programs developing BB106,” Bexson Biomedical CEO Gregg Peterson said in the release. “FDA approval is a long process, but every milestone reached is one step closer to providing patients with an alternative to opioids for pain management.”

Future clinical trials will test the effect the drug-device combination has in acute pain management as an alternative to opioid pain medications or as an added therapy to lower the need for opioids after serious surgeries, Bexson said. With FDA guidance, the company is now applying BB106 toward mental health conditions.

“Our subcutaneous ketamine formulation and pump technology has been modular by design, allowing us to tune dosing profiles to a variety of mental health conditions as our program advances,” added Bexson Co-Founder & CSO Dr. Jeffrey Becker. “We are designing our parenteral ketamine delivery system to be convenient, controlled and consistent.  This can solve many of the problems that still exist in office-based delivery of ketamine for depression and suicidal ideation, but also for ketamine-assisted trauma therapy.”

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Neurological, Pain Management Tagged With: Bexson Biomedical, FDA, Stevanato Group

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS